A large trial of dexamethasone has shown the low-cost steroid can cut deaths in patients hospitalized with severe COVID-19 by up to a third, making it the first drug to show any lifesaving benefits for these patients.
The data are in contrast with disappointing results from multiple trials of repurposed antimalarial hydroxychloroquine, and even Gilead Sciences Inc